SynbioTech is set to present its groundbreaking TWK10® research and microbiome CDMO platform at Vitafoods Asia 2026, targeting the rapidly emerging companion-nutrition market for GLP-1 users.
- SynbioTech will exhibit TWK10® at Vitafoods Asia 2026 in Bangkok.
- TWK10® targets the 'gut-muscle axis' to support muscle mass during weight loss.
- The technology addresses the nutritional gaps created by GLP-1 therapies.
- Backed by 27 scientific publications and 18 global patents.
As the global healthcare landscape shifts toward advanced weight management, SynbioTech, a leading biotechnology firm, has announced its participation in Vitafoods Asia 2026. The company will present its internationally acclaimed Lactiplantibacillus plantarum TWK10® and its integrated microbiome CDMO platform at the Queen Sirikit National Convention Center in Bangkok from September 2-4.
The emergence of GLP-1-based therapies has fundamentally changed how the world approaches weight management. However, as appetite control becomes more efficient, a new challenge arises: ensuring that consumers maintain muscle mass and nutrient density while consuming fewer calories. SynbioTech’s TWK10® is designed to bridge this critical gap.
Why This Matters
BozokMedia analysis shows that the GLP-1 drug market is projected by Morgan Stanley Research to reach a staggering US$190 billion by 2035. This massive growth is creating a secondary market for 'companion nutrition'—products specifically formulated to support protein utilization, muscle integrity, and metabolic health in users of weight-loss medications.
GLP-1 has broadened the weight management conversation beyond appetite control; the new frontier is ensuring that eating less does not mean being less nourished.
Clinical Evidence and Efficacy: Research into TWK10® has demonstrated significant benefits for the 'gut-muscle axis.' In human clinical trials, the strain showed an ability to increase peak blood concentrations of total BCAAs by 6.9% and total amino acids by 3.1%. Furthermore, in studies involving older adults, TWK10® supplementation led to a remarkable 51% improvement in 30-second chair-stand performance and a 13% increase in hand grip strength.
Comparative Impact of TWK10®
| Metric | Observed Improvement |
|---|---|
| Total BCAAs | +6.9% |
| Hand Grip Strength | +13% |
| Chair-Stand Performance | +51% |
| Timed Up-and-Go Speed | 16.8% faster |
Beyond clinical efficacy, SynbioTech has prioritized global market readiness. TWK10® holds regulatory milestones including self-affirmed GRAS status in the United States, functional claim recognition in Korea, and registration in Malaysia and Japan. This makes it a highly scalable solution for global brands looking to enter the women's health and active aging sectors.
Frequently Asked Questions
1. What is the significance of the gut-muscle axis?
It refers to the bidirectional communication between the gut microbiota and skeletal muscle, which influences muscle mass and physical function.
2. How does TWK10® support GLP-1 users?
It helps optimize amino acid absorption and muscle maintenance, countering the potential muscle loss often associated with rapid weight loss from GLP-1 drugs.
